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Introduction: We report a case of an adult patient with human immunodeficiency virus (HIV), acute respiratory
distress syndrome (ARDS) and ventilator associated pneumonia (VAP) caused by multidrug resistant (MDR) bacteria
that was successfully managed with veno-venous extracorporeal membrane oxygenation (ECMO).
Case report: A 25 year old male with no significant past medical history had been admitted to a local hospital due
to dyspnea and fever. His pulmonary function subsequently failed necessitating mechanical ventilation (MV) and
introduction of ECMO support. The patient was transported for 300 km by road on ECMO to a tertiary medical
center. The diagnosis of ARDS, HIV infection and MDR bacterial and fungal VAP was made. Patient was successfully
treated with antiretroviral therapy (ART), anti-infective agents and 58 days of veno-venous ECMO support, with
complete resolution of the respiratory symptoms.
Conclusion: HIV infected patients with ARDS and MDR bacterial VAP whose HIV replication is controlled by ART
could be successfully managed with ECMO.
Keywords: HIV, veno-venous ECMO, ARDS, multidrug resistant bacteria, VAPBackground
According to Berlin definition [1] acute respiratory dis-
tress syndrome (ARDS) is characterized by 1) lung injury
of acute onset, within 1 week of an apparent clinical in-
sult and with progression of respiratory symptoms; 2) bi-
lateral opacities on chest imaging not explained by other
pulmonary pathology (e.g. pleural effusion, pneumo-
thorax, or nodules); 3) respiratory failure not explained
by heart failure or volume overload; 4) mechanical venti-
lation with decreased PaO2/FiO2 (ratio of partial pres-
sure of arterial oxygen to fraction of inspired oxygen).* Correspondence: laimonas.griskevicius@santa.lt
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article, unless otherwise stated.Extracorporeal membrane oxygenation (ECMO) is
salvage therapy for selected group of patients with gas-
exchange failure refractory to mechanical ventilation
(MV). Severe hypoxemia despite the application of high
levels of PEEP or uncompensated hypercapnia are the
main indications for ECMO treatment. Mechanical
ventilation at high settings (FiO2 90%, Pplat >30 mmHg)
for more than 7 days, immunosupression and intracra-
nial hemorrhage are the main contraindications for
using this mode of treatment. ECMO is associated with
considerable risks for the patient, including but not
limited to bleeding, infection or mechanical failure of
the ECMO circuit [2]. Recently, ECMO has been shown
to be very effective in treating ARDS patients during
H1N1 pandemic [3] and successful use of ECMO in im-
munocompromised patients has been reported [4,5].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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corporeal life support.
The purpose of this report is to describe an human
immunodeficiency virus (HIV) infected patient with
ARDS complicated by multidrug resistant (MDR) bacterial
and fungal ventilator associated pneumonia (VAP) who
was successfully managed with veno-venous ECMO and
off-label doses of antimicrobial agents.
Case presentation
A 25 year old male with no significant past medical his-
tory was admitted to a local hospital due to dyspnea
and fever of 39°C. The patient’s pulmonary computer
tomography (CT) scan was consistent with alveolitis. Spu-
tum and blood cultures were negative. Patient received
empirical Amoxicillin prior to hospitalisation and Cefur-
oxime in hospital without any improvement. For sus-
pected allergic alveolitis prednisolone 40 mg daily for
8 days was administered. As a result of worsening of re-
spiratory function on day 10 of initial hospitalization, the
patient was transferred to intensive care unit (ICU). 1
gram of methylprednisolone once, followed by three con-
secutive doses of 120 mg/per day were administered.
Pulmonary function deteriorated and mechanical venti-
lation was initiated on day 6 in intensive care unit stay.
No signs of any other organ system dysfunction were
evident. Antibiotic therapy was changed to Imipenem
and Vancomycine. On day 11 of MV, the patient’s re-
spiratory function deteriorated substantially. The deci-
sion was made to transfer the patient to Vilnius
University Hospital Santariskiu Klinikos (VUHSK) with
facilities for ECMO treatment.Figure 1 Chest x-ray on admission at VUHSK (3 hours after ECMO staWhen transport team arrived, tidal volume was de-
creasing to critical levels trying to achieve safe ventila-
tion pressures, the patient had drained pneumothorax,
paO2/FiO2 of 84 mmHg on 85% of FiO2 and 16 cm H2O
of PEEP. As well patient had permissive hypercapnia
with CO2 of 87 mmHg; Murray score was 4 (up to four
points in each of four categories; PaO2/FiO2, number of
quadrants with alveolar consolidation, PEEP, and compli-
ance) [6]; pulmonary compliance was only 4 ml/cm
H2O; with pressure control ventilation of 30 cm H2O
the inspired tidal volume was only 2 ml/kg. The decision
was made to place the patient on veno-venous ECMO
before the transfer because paO2/FiO2 of less than
80 mmHg on 90% of FiO2 and Murray score of 3–4
identifies the risk of mortality of 80% with conventional
treatment and is an indication for initiation of extracor-
poreal life support according to the extracorporeal life
support organization guidelines (www.elso.med.umich.
edu/Guidelines.html). 23 French drainage cannula (Bio-
Medicus, Medtronic Inc., Minneapolis, USA) was inserted
percutaneously into inferior vena cava via femoral ap-
proach and 19 French return cannula was inserted into
the left internal jugular vein. ECMO circuit consisted of
bioline coated Quadrox PLS oxygenator and Rotaflow
centrifugal pump (Maquet Cardiopulmonary AG, Rastatt,
Germany). The patient was uneventfully transported for
300 km (200 minutes) by road ambulance to VUHSK,
ECMO flow was 6 l/min.
On admission to VUHSK, the patient’s lung compli-
ance was 3–4 ml/cm H2O, his respiratory tidal volume
was only 1–2 mL/kg to keep the ventilation pressure
safe at <30 cm H2O. The patient had lung infiltration ofrt).
Table 1 Nosocomial infections and treatment





















1 BAL/CAT BAL/CAT BAL/BL 93 Colistin 1 i.v. 13.5 m. IU
Ganciclovir - i.v. 0.8 g
3 SP 165 Colistin 1 i.v. 13.5 m. IU
8 BAL 77 Anidulafungin 0.125 i.v. 0.1 g
11 BAL 151 Colistin 1 i.v. 13.5 m. IU
16 BAL 286 Ciprofloxacin 0.5 i.v. 1.2 g
24 BAL/BL 22 Ciprofloxacin 0.5 i.v. 2.4 g
Colistin 2 i.v./inh 13.5/6 m. IU
28, 35, 39 BAL/ UR 149-157 Colistin 0.5-2 i.v./inh 13.5/9 m. IU
43 BAL/UR 162 Ampicillin Sulbactam 2 i.v. 36 g
51 BAL 98 Cefepim 4 i.v. 6 g
63 BAL 86 Colistin 0.5 i.v./inh 13.5/15 m. IU
65, 70 BL/ CAT 73 Amphotericin B 0.5 i.v. 0.08 g
75 CAT CAT CAT 90 Ciprofloxacin 0.38 i.v. 2.4 g
Cefepim 4 i.v. 6 g
Imipenem 1 i.v. 3 g
Amphotericin B 0.19 i.v. 0.08 g
77 CAT 108 Imipenem <0.25 i.v. 3 g
ICU – intensive care unit, CRP – C-reactive protein, MIC – minimal inhibitory concentration, BL – blood, BAL – bronchoalveolar lavage, CAT – catheter, UR – urine, i.v. – intravenous, inh.–inhaled, m. – million,
IU – international units.
*Acinetobacter baumanii was carbapenems (Imipenem, Meropenem MIC 32 mg/L), aminoglycosyde (Amikacin MIC 256 mg/L, Gentamycin MIC 24 mg/L) and cephalosporin (Cefepim MIC 48 mg/L) resistant;




















Table 2 Complications and their treatment during ECMO
ICU day Complications Treatment/Procedures
1-59 Bilateral pneumothorax Pleural cavity drainage
25, 31, 51 Pulmonary hemorrhage Endobroncheal hemostasis
38 Tilt of left jugular vein cannula with blood loss of 2 liters Cannula reinserted, transfusions of packed red blood cells and platelets
46 Blood-clot masses in pleural cavity Open right side thoracotomy with clot removal and lung decortication
48 Left side tension pneumothorax with cardiogenic shock Pleural cavity drainage, resuscitation
52 Bleeding from tracheostoma Endobroncheal hemostasis
Endrobronchial clot-masses Bronchoscopy and clot-mass removal
60 Cannula associated deep vein thrombosis Heparin, compression therapy
Samalavicius et al. AIDS Research and Therapy 2014, 11:37 Page 4 of 6
http://www.aidsrestherapy.com/content/11/1/374 quadrants seen on chest x-ray (Figure 1). The white
blood cell (WBC) count was 8.72 × 109/L (neutrophils
7.71 × 109/L, lymphocytes 0.66 × 109/L), platelets 257 ×
109/L, hemoglobin 109 g/l, lactate 1.36 mmol/L and
C-reactive protein (CRP) was 93 mg/L. On the first day
at VUHSK, the patient was confirmed HIV positive
(positive anti-HIV ½ Ag/Ab, Western Blot analysis
showed three bands (p41, gp120 and p51) and HIV-1
RNA was 2.22 million copies/mL), his CD4 cell count was
134 cells/μL. The blood sample was positive for CMV
DNA (442420 copies/mL). The bronchoalveolar lavage
(BAL) fluid WBC count was 1.17 × 109/L (99% neutro-
phils) and was positive for CMV DNA (76740 copies/mL),
Candida glabrata and MDR Acinetobacter baumanii. The
diagnosis of ARDS, HIV infection, nosocomial VAP and
possible CMV pneumonitis was made. Colistin, Linezolid,
Imipenem, Ganciclovir and Anidulafungin were started.
ART consisting of Kivexa (Abacavir and Lamivudine)
and Kaletra (Lopinavir and Ritonavir) was initiated. TheFigure 2 Chest x-ray after weaning off ECMO.patient was continued with MV, full intensive care and
intermittent vasopressor support. Blood flow during
ECMO was tailored to achieve acceptable oxygenation.
Ventilator settings were reduced to protective ventilation
mode. During the ICU stay, aggressive treatment of
numerous nosocomial infections was required (Table 1).
Complications during ECMO are detailed in Table 2.
Despite aggressive treatment, improvement of pulmon-
ary mechanics was slow (tidal volume with Ppeak 30 cm
H2O was only up to 2 ml/kg, compliance remained at
1–4 ml/cm H2O). For the downregulation of immune re-
constitution inflammatory syndrome, intravenous methyl-
prednisolone 1 mg/kg/dose per day for 7 days was
administered on ECMO day 18 and then gradually tapered
off over 15 days. This resulted in improved lung function
(tidal volume increased to 4.4 mL/kg with Ppeak 27
cmH2O and compliance 9–10 ml/cm H2O).
The first oxygenator was exchanged on day 38 after
decrease in function. The patient was weaned off ECMO
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capnic respiratory failure developed (pCO2 190 mmHg,
pH 7.05). The veno-venous ECMO was reinstituted with
successful weaning after 48 hours. MV was continued
for additional 18 days.
After 70 days of ART, the patient’s CD4 cell count in-
creased to 268 cells/μL and the HIV-1 viral load became
591 copies/mL, lung chest X-ray is shown in Figure 2.
The patient was transferred to a general ward and later
discharged from hospital to continue rehabilitation. At
the last clinic visit 115 days after having been discharged
from ICU, the patient reported good health, had no pul-
monary symptoms, could walk unassisted for more than
2 kilometers.
In total, 51 packed red blood cells and 14 platelet
units were transfused. The total duration of ECMO was
58 days. The total MV duration was 87 days (11 pre
ECMO, 58 ECMO and 18 post ECMO). The total VUHSK
ICU stay was 84 days.
Discussion
ECMO use in immunocompromised patients is contro-
versial because of high mortality [7-9]. To the best of
our knowledge, there is only one report of ECMO use in
HIV infected patient [5]. We had not been aware of the
patient’s HIV infection and thus were not biased when
deciding to initiate ECMO support. Also, our patient
may have had an early stage of HIV infection as wit-
nessed by a high HIV-1 viral load in parallel with a weak
antibody band spectrum on Western Blot analysis and
relatively rapid CD4 count recovery.
Importantly, our patient had a predominant pulmon-
ary failure while the function of other organs was rela-
tively preserved making veno-venous ECMO a good
choice of gas-exchange support while anti-infective ther-
apy took effect. Also, we chose an aggressive preemptive
approach to diagnose and treat nosocomial superinfec-
tions. Increased cardiac output, leaky capillaries, enlarged
volume of distribution and impaired tissue penetration in
septic patients may lead to an inadequate concentration of
antimicrobial agent at the target site [10]. Also, due to se-
questration and increased volume of distribution patients
on ECMO are at risk of suboptimal antimicrobial therapy
[11]. Therefore, there is a tendency to use higher doses of
antimicrobial agents in critically ill patients. In our case,
antibiotics were changed as soon as nosocomial bacteria
were identified at doses that in many cases were consider-
ably higher (Table 1) [12-14] than indicated in the drug
label. We did not observe unacceptable antibiotic related
toxicity.
ART was initiated as soon as HIV positivity was
confirmed. Of note, ART suppresses HIV replication
and may cause immune reconstitution inflammatory
syndrome [15]. We administered a short course ofmethylprednisolone resulting in improved lung func-
tion. A recent meta-analysis showed a possibility of re-
duced mortality and increased ventilator free days
with steroids in ARDS [16].
Common complications during ECMO are pneumo-
nia, sepsis and bleeding especially associated with invasive
procedures [17]. In our case, pulmonary hemorrhage,
bleeding from the cannulation site and pneumothorax (in-
cluding one case of tension pneumothorax) were observed
necessitating surgical and medical intervention (Table 2).
After first weaning off ECMO we observed hypercapnic
respiratory failure leading to hemodynamic instability.
This emphasizes uneven pulmonary gas exchange recon-
stitution with CO2 exchange recovery often trailing that of
O2 [18].
Conclusions
In individual cases, ECMO could be succesfully applied
in HIV infected patients with ARDS refractory to con-
ventional treatment and ventilator-associated pneumo-
nia caused by multidrug resistant bacteria whose HIV
replication is controlled by antiretroviral therapy. Long-
distance transportation on ECMO may be attempted in
selected cases.
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